Journal of the American Academy of Dermatology
-
J. Am. Acad. Dermatol. · Mar 2020
Computer algorithms show potential for improving dermatologists' accuracy to diagnose cutaneous melanoma: Results of the International Skin Imaging Collaboration 2017.
Computer vision has promise in image-based cutaneous melanoma diagnosis but clinical utility is uncertain. ⋯ Accumulating evidence suggests that deep neural networks can classify skin images of melanoma and its benign mimickers with high accuracy and potentially improve human performance.
-
J. Am. Acad. Dermatol. · Feb 2020
Randomized Controlled TrialLong-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial.
Randomized controlled trials have shown the efficacy and safety of brodalumab in patients with moderate to severe plaque psoriasis. ⋯ Brodalumab is well tolerated and showed robust efficacy for more than 2 years.
-
J. Am. Acad. Dermatol. · Feb 2020
Randomized Controlled TrialRuxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, randomized, vehicle-controlled phase 2 study.
There are currently no treatments for alopecia areata (AA) that are universally effective or approved by the US Food and Drug Administration. Oral ruxolitinib has shown efficacy in extensive AA. Ruxolitinib cream would potentially avoid systemic adverse effects. ⋯ The 1.5% ruxolitinib cream did not have a significant effect in patients with AA.
-
J. Am. Acad. Dermatol. · Feb 2020
Multicenter StudyDupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study.
Significant unmet need exists for long-term treatment of moderate to severe atopic dermatitis (AD). ⋯ The safety and efficacy profile from this study supports the role of dupilumab as continuous long-term treatment for patients with moderate to severe AD.
-
J. Am. Acad. Dermatol. · Jan 2020
Characterizing the role of dermatologists in developing artificial intelligence for assessment of skin cancer: A systematic review.
The use of artificial intelligence (AI) for skin cancer assessment has been an emerging topic in dermatology. Leadership of dermatologists is necessary in defining how these technologies fit into clinical practice. ⋯ Greater involvement of dermatologists is needed in thinking through issues in data collection, data set biases, and applications of technology. Dermatologists can provide access to large, diverse data sets that are increasingly important for building these models.